Table 1.

Patient demographics and baseline disease characteristics

Total (N = 70)
Gender, n (%)
 Female10 (14.3)
 Male60 (85.7)
Mean age at enrollment, years (range)55.4 ± 12.3 (28–78)
Age group, n (%)
 ≤65 years52 (74.3)
 >65 years18 (25.7)
ECOG PS, n (%)
 038 (54.3)
 132 (45.7)
Target lesions, n (%)
 117 (24.3)
 235 (50.0)
 312 (17.1)
 44 (5.7)
 52 (2.9)
Sites of disease, n (%)
 Adrenal gland3 (4.3)
 Bone5 (7.1)
 Liver61 (87.1)
 Lung33 (47.1)
 Lymph node20 (28.6)
 Other15 (21.4)
BCLC stage, n (%)
 B5 (7.1)
 C65 (92.9)
Symptoms of hepatobiliary cancer present at initial diagnosisa, n (%)35 (50.0)
Etiology of HCCb, n (%)
 Hepatitis B53 (75.7)
 Hepatitis C12 (17.1)
 Alcohol use10 (14.3)
TNM grading of hepatobiliary cancer at study entry, n (%)
 Stage II2 (2.9)
 Stage III22 (31.4)
 Stage IV46 (65.7)
Macrovascular invasion/extrahepatic spread, n (%)
 Macrovascular invasion present; no extrahepatic spread17 (24.3)
 Extrahepatic spread present; no macrovascular invasion19 (27.1)
 Both conditions present27 (38.6)
 Both conditions absent7 (10.0)
Liver cirrhosisc, n (%)58 (82.9)
Alpha fetoprotein (ng/mL)d, n (%)
 <400 ng/mL36 (51.4)
 ≥400 ng/mL32 (45.7)
Prior locoregional treatment for HCC (in ≥5% of patients), n (%)
 Transarterial chemoembolization32 (45.7)
 Hepatectomy, partial10 (14.3)
 Radiofrequency ablation9 (12.9)
 Lobectomy5 (7.1)
 Percutaneous ethanol injection4 (5.7)
 Transarterial embolization4 (5.7)
Median time from initial diagnosis to start of study treatment, weeks36.1
Median time from first progression to start of study treatment, weeks29.9
Median time from most recent progression to start of study treatment, weeks5.5

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; TNM, tumor node metastases.

  • aUnknown, n = 7; bmultiple diseases per patient are possible, unknown, n = 4; cmissing, n = 1; dmissing, n = 2.